Silence Therapeutics Plc's Cash & cash equivalent grew by 243.71 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Silence Therapeutics Plc's Quick Ratio to 22, above Silence Therapeutics Plc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 174 other companies have achieved higher Quick Ratio than Silence Therapeutics Plc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 519 to 649.

Explain Quick Ratio?
How much Cash & cash equivalents SLN�s has?
What are SLN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/SLN/financial-strength

https://api.csimarket.com/api/v1/companies/SLN/fundamentals

https://api.csimarket.com/api/v1/companies/SLN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

SLN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-35.71 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	142.35 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	22	Subscribe	Subscribe	Subscribe	Subscribe
SLN's Total Ranking	# 649	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-11.44 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	243.71 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 175
Healthcare Sector	# 277
Overall Market	# 649

Quick Ratio Statistics
High	Average	Low
10.35	6.53	4.67
(Dec 31 2024)		(Sep 30 2025)

Financial Statements
Silence Therapeutics Plc's Current Liabilities	$ 11 Millions	Visit SLN's Balance sheet
Silence Therapeutics Plc's Cash & cash equivalent	$ 248 Millions	Visit SLN's Balance sheet
Source of SLN's Sales		Visit SLN's Sales by Geography

Cumulative Silence Therapeutics Plc's Quick Ratio

SLN's Quick Ratio for the trailling 12 Months

SLN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-29.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-15.94 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	9.37	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3583	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-10.98 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	44.16 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to SLN Financial Strength Comparisons >> Go to Compare SLN Quick Ratio to its Competitors

On the trailing twelve months basis SLN Cash & cash equivalent more than doubled by 142.35 % in Q3 2026 year on year, while Current Liabilities fell to $11 millions, this led to increase in in Silence Therapeutics Plc's Quick Ratio to 9.37, above SLN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 422 other companies have achieved higher Quick Ratio than Silence Therapeutics Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3571 to 3583.

Explain Quick Ratio?
How much Cash & cash equivalents SLN�s has?
What are SLN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 423
Healthcare Sector	# 858
Within the Market	# 3583

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.62	6.79	6.01
(Jun 30 2025)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Q32 Bio Inc	56.05	$ 289.587 Millions	$ 5.167 Millions
Rallybio Corporation	51.94	$ 90.693 Millions	$ 1.746 Millions
Enliven Therapeutics Inc	45.41	$ 884.351 Millions	$ 19.473 Millions
Vyne Therapeutics Inc	41.29	$ 268.860 Millions	$ 6.511 Millions
Bicara Therapeutics Inc	40.75	$ 442.346 Millions	$ 10.856 Millions
Tango Therapeutics Inc	38.85	$ 977.503 Millions	$ 25.164 Millions
Trevi Therapeutics Inc	38.05	$ 299.408 Millions	$ 7.869 Millions
Fulcrum Therapeutics Inc	35.70	$ 306.545 Millions	$ 8.587 Millions
Boundless Bio Inc	33.60	$ 62.894 Millions	$ 1.872 Millions
Avalyn Pharma Inc	32.64	$ 422.814 Millions	$ 12.955 Millions
Immix Biopharma Inc	30.89	$ 336.303 Millions	$ 10.889 Millions
Minerva Neurosciences Inc	30.46	$ 76.945 Millions	$ 2.526 Millions
Contineum Therapeutics Inc	30.45	$ 244.484 Millions	$ 8.028 Millions
Pasithea Therapeutics Corp	29.91	$ 82.419 Millions	$ 2.756 Millions
Latigo Biotherapeutics, Inc.	28.73	$ 401.241 Millions	$ 13.964 Millions
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Silo Pharma Inc	22.91	$ 8.051 Millions	$ 0.351 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Silence Therapeutics Plc	22.00	$ 247.659 Millions	$ 11.259 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Relmada Therapeutics Inc	19.30	$ 202.123 Millions	$ 10.474 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Equillium Inc	18.92	$ 53.322 Millions	$ 2.819 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions

Date modified: 2026-11-14T08:51:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.